Drugs / Eziclen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03008460 | Oct 2017 → Feb 2020 | digestive system disorder | Ipsen | Completed | Missed primary |
| Phase 3 | NCT02321462 | Mar → Dec 2015 | — | Ipsen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eziclen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02321462 ↗ |
| Known as | Izinova | “Eziclen®/Izinova®” NCT03008460 ↗ |
| Modality | Other / unclassified | “oral sulfate solution (OSS)” PMID 36821851 ↗ Feb 2023 |
| Route | Oral | “Eziclen solution administered orally” NCT02321462 ↗ |